Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00757 | 34978298 | J Vis Exp | Isolation and Characterization of Mouse Primary Liver Sinusoidal Endothelial Cells. | 2021 | Details |
| A00759 | 34977520 | JHEP Rep | Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions. | 2021 | Details |
| A00760 | 34977519 | JHEP Rep | Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis. | 2021 | Details |
| A00762 | 34977507 | iScience | In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications. | 2021 | Details |
| A00775 | 34971904 | Biochem Biophys Res Commun | Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. | 2021 | Details |
| A00776 | 34971806 | Clin Gastroenterol Hepatol | Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. | 2021 | Details |
| A00777 | 34971370 | J Clin Endocrinol Metab | Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00778 | 34970870 | Hepatol Commun | Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. | 2021 | Details |
| A00790 | 34966282 | Front Pharmacol | Coffee Consumption and Non-alcoholic Fatty Liver Disease: An Umbrella Review and a Systematic Review and Meta-analysis. | 2021 | Details |
| A00791 | 34966134 | Eur J Gastroenterol Hepatol | Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease. | 2021 | Details |
| A00797 | 34964117 | Compr Physiol | Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease. | 2021 | Details |
| A00799 | 34962146 | Metab Syndr Relat Disord | Prevalence of Hepatic Steatosis and Fibrosis in the United States. | 2021 | Details |
| A00802 | 34960005 | Nutrients | Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial. | 2021 | Details |
| A00807 | 34959755 | Nutrients | The Effects of Butyrate on Induced Metabolic-Associated Fatty Liver Disease in Precision-Cut Liver Slices. | 2021 | Details |
| A00814 | 34958922 | Clin Gastroenterol Hepatol | Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018. | 2021 | Details |
| A00815 | 34958817 | Metabolism | Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. | 2021 | Details |
| A00816 | 34958747 | Clin Gastroenterol Hepatol | Food Insecurity is Associated With Mortality Among U.S. Adults With Nonalcoholic Fatty Liver Disease and Advanced Fibrosis. | 2021 | Details |
| A00821 | 34957156 | Front Med (Lausanne) | Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System. | 2021 | Details |
| A00826 | 34956080 | Front Endocrinol (Lausanne) | Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2021 | Details |
| A00831 | 34954593 | Eur J Med Chem | Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents. | 2021 | Details |
| A00833 | 34954342 | Biochim Biophys Acta Mol Basis Dis | Role of AKR1B10 and AKR1B8 in the pathogenesis of non-alcoholic steatohepatitis (NASH) in mouse. | 2021 | Details |
| A00835 | 34953171 | J Magn Reson Imaging | The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis. | 2021 | Details |
| A00836 | 34953098 | Liver Int | Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. | 2022 | Details |
| A00838 | 34951993 | Gastroenterology | Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. | 2021 | Details |
| A00839 | 34951726 | Hepatology | Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A00840 | 34951153 | Hepatol Commun | Angiotensin Converting Enzyme-2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver. | 2021 | Details |
| A00842 | 34950996 | Indian J Gastroenterol | Fetuin-A in newly detected type 2 diabetes mellitus as a marker of non-alcoholic fatty liver disease. | 2021 | Details |
| A00850 | 34948230 | Int J Mol Sci | It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them? | 2021 | Details |
| A00856 | 34945051 | J Clin Med | Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. | 2021 | Details |
| A00857 | 34945016 | J Clin Med | Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review. | 2021 | Details |
| A00858 | 34944736 | Biomedicines | Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00859 | 34944732 | Biomedicines | Therapeutic Opportunities of IL-22 in Non-Alcoholic Fatty Liver Disease: From Molecular Mechanisms to Clinical Applications. | 2021 | Details |
| A00860 | 34944730 | Biomedicines | Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem. | 2021 | Details |
| A00864 | 34944706 | Biomedicines | The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis. | 2021 | Details |
| A00865 | 34944682 | Biomedicines | Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic. | 2021 | Details |
| A00867 | 34944593 | Biomedicines | Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00868 | 34944567 | Biomedicines | Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients. | 2021 | Details |
| A00870 | 34944452 | Biomolecules | Digital Pathology Enables Automated and Quantitative Assessment of Inflammatory Activity in Patients with Chronic Liver Disease. | 2021 | Details |
| A00871 | 34944021 | Cells | IL-19 Contributes to the Development of Nonalcoholic Steatohepatitis by Altering Lipid Metabolism. | 2021 | Details |
| A00873 | 34943942 | Cells | MXD3 Promotes Obesity and the Androgen Receptor Signaling Pathway in Gender-Disparity Hepatocarcinogenesis. | 2021 | Details |
| A00874 | 34943908 | Cells | Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00875 | 34943814 | Cells | Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2. | 2021 | Details |
| A00876 | 34943809 | Cells | Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00877 | 34943553 | Diagnostics (Basel) | Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up. | 2021 | Details |
| A00880 | 34943134 | Antioxidants (Basel) | Hepatoprotective Effect of Bee Bread in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Rats: Impact on Oxidative Stress and Inflammation. | 2021 | Details |
| A00882 | 34943103 | Antioxidants (Basel) | Association of Serum Bilirubin and Functional Variants of Heme Oxygenase 1 and Bilirubin UDP-Glucuronosyl Transferase Genes in Czech Adult Patients with Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00893 | 34938631 | Cureus | Glycogenic Hepatopathy as the Etiology of Abnormal Liver Chemistries in an Uncontrolled Type I Diabetic Patient. | 2021 | Details |
| A00894 | 34938271 | Front Endocrinol (Lausanne) | Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00896 | 34938193 | Front Pharmacol | Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. | 2021 | Details |
| A00898 | 34935645 | JCI Insight | Maternal Western diet exposure increases periportal fibrosis beginning in utero in nonhuman primate offspring. | 2021 | Details |
| A00900 | 34935140 | Br J Pharmacol | Mineralocorticoid receptors in non-alcoholic fatty liver disease. | 2022 | Details |
| A00901 | 34934197 | Acta Pharmacol Sin | GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. | 2021 | Details |
| A00902 | 34934162 | Sci Rep | Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes. | 2021 | Details |
| A00905 | 34933428 | Zhonghua Gan Zang Bing Za Zhi | [Studying the correlation between ferritin and non-alcoholic fatty liver disease]. | 2021 | Details |
| A00908 | 34933425 | Zhonghua Gan Zang Bing Za Zhi | [Intestinal flora polymorphisms with different lesional stages in an animal model of MAFLD]. | 2021 | Details |
| A00913 | 34932136 | Diabetologia | Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. | 2021 | Details |
| A00916 | 34931080 | Nat Metab | Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. | 2021 | Details |
| A00918 | 34929996 | Minerva Gastroenterol (Torino) | Evaluation of MACK-3 parameters, metabolic and fibrotic characteristics of non-alcoholic fatty liver disease patients with hypertension. | 2021 | Details |
| A00919 | 34929490 | EBioMedicine | Peripheral immune cells in NAFLD patients: A spyhole to disease progression. | 2021 | Details |
| A00920 | 34929391 | Clin Gastroenterol Hepatol | Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999-2016. | 2021 | Details |
| A00921 | 34929318 | Gastroenterol Hepatol | Changes in indications for outpatient percutaneous liver biopsy over 5 years: from hepatitis C to fatty liver disease. | 2021 | Details |
| A00923 | 34928415 | Eur Radiol | MR elastography in nonalcoholic fatty liver disease: inter-center and inter-analysis-method measurement reproducibility and accuracy at 3T. | 2021 | Details |
| A00927 | 34927277 | Aliment Pharmacol Ther | Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. | 2021 | Details |
| A00929 | 34927020 | iScience | Liver sphingomyelin synthase 1 deficiency causes steatosis, steatohepatitis, fibrosis, and tumorigenesis: An effect of glucosylceramide accumulation. | 2021 | Details |
| A00930 | 34926735 | Regen Ther | Characterization of adipose tissue-derived stromal cells of mice with nonalcoholic fatty liver disease and their use for liver repair. | 2021 | Details |
| A00932 | 34925237 | Front Endocrinol (Lausanne) | Current and Potential Therapies Targeting Inflammation in NASH. | 2021 | Details |
| A00948 | 34922062 | Clin Res Hepatol Gastroenterol | Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners. | 2021 | Details |
| A00951 | 34921208 | Sci Rep | Dual role of neutrophils in modulating liver injury and fibrosis during development and resolution of diet-induced murine steatohepatitis. | 2021 | Details |
| A00956 | 34919684 | J Nutr | A Specifically Tailored Multistrain Probiotic and Micronutrient Mixture Affects Nonalcoholic Fatty Liver Disease-Related Markers in Patients with Obesity after Mini Gastric Bypass Surgery. | 2022 | Details |
| A00959 | 34918671 | Medicine (Baltimore) | Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States. | 2021 | Details |
| A00964 | 34917640 | Front Med (Lausanne) | Association of Cholecystectomy With Liver Fibrosis and Cirrhosis Among Adults in the USA: A Population-Based Propensity Score-Matched Study. | 2021 | Details |
| A00971 | 34915054 | J Hepatol | A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. | 2021 | Details |
| A00973 | 34914973 | Exp Mol Pathol | TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop. | 2021 | Details |
| A00976 | 34914039 | Indian J Gastroenterol | Endoscopic sleeve gastroplasty - minimally invasive treatment for non-alcoholic fatty liver disease and obesity. | 2021 | Details |
| A00977 | 34912244 | Front Physiol | Translational Control in Liver Disease. | 2021 | Details |
| A00987 | 34909677 | Curr Res Pharmacol Drug Discov | ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score. | 2021 | Details |
| A00988 | 34909410 | Psoriasis (Auckl) | Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. | 2021 | Details |
| A00993 | 34907642 | J Cell Mol Med | Non-coding RNA-associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma. | 2021 | Details |
| A01003 | 34905051 | J Clin Endocrinol Metab | Fibrogenesis marker PRO-C3 is higher in advanced liver fibrosis and improves in patients undergoing bariatric surgery. | 2022 | Details |
| A01005 | 34904923 | Expert Opin Ther Targets | PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. | 2021 | Details |
| A01011 | 34904026 | World J Hepatol | Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. | 2021 | Details |
| A01016 | 34902629 | Cell Mol Gastroenterol Hepatol | Escherichia fergusonii Promotes Nonobese Nonalcoholic Fatty Liver Disease by Interfering With Host Hepatic Lipid Metabolism Through Its Own msRNA 23487. | 2021 | Details |
| A01017 | 34902220 | J Dig Dis | The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C. | 2022 | Details |
| A01020 | 34901236 | Front Cardiovasc Med | Statins in Non-alcoholic Steatohepatitis. | 2021 | Details |
| A01025 | 34899679 | Front Immunol | Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. | 2021 | Details |
| A01030 | 34896638 | Ann Hepatol | Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis. | 2021 | Details |
| A01031 | 34896404 | J Hepatol | The fecal mycobiome in non-alcoholic fatty liver disease. | 2021 | Details |
| A01040 | 34893685 | Acta Pharmacol Sin | The miR-23-27-24 cluster: an emerging target in NAFLD pathogenesis. | 2021 | Details |
| A01048 | 34889100 | J Med Chem | Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor. | 2021 | Details |
| A01050 | 34887931 | Evid Based Complement Alternat Med | Pharmacodynamic Evaluation of the Gexia Zhuyu Decoction in the Treatment of NAFLD and the Molecular Mechanism Underlying the TRPM4 Pathway Regulation. | 2021 | Details |
| A01052 | 34887649 | World J Gastroenterol | Immunoglobulin G in non-alcoholic steatohepatitis predicts clinical outcome: A prospective multi-centre cohort study. | 2021 | Details |
| A01053 | 34887631 | World J Gastroenterol | Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach. | 2021 | Details |
| A01054 | 34886991 | J Comp Pathol | Role of Plin5 Deficiency in Progression of Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice. | 2021 | Details |
| A01068 | 34881283 | Front Nutr | Caffeine and EGCG Alleviate High-Trans Fatty Acid and High-Carbohydrate Diet-Induced NASH in Mice: Commonality and Specificity. | 2021 | Details |
| A01072 | 34878523 | Endocrinology | Adipose-specific VDR Deletion Leads to Hepatic Steatosis in Female Mice Fed a Low-Fat Diet. | 2022 | Details |
| A01075 | 34877270 | World J Clin Cases | Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. | 2021 | Details |
| A01078 | 34875824 | J Prev Med Public Health | Association Between Low Muscle Mass and Non-alcoholic Fatty Liver Disease Diagnosed Using Ultrasonography, Magnetic Resonance Imaging Derived Proton Density Fat Fraction, and Comprehensive NAFLD Score in Korea. | 2021 | Details |
| A01084 | 34873633 | Eur Radiol Exp | Advances in liver US, CT, and MRI: moving toward the future. | 2021 | Details |
| A01085 | 34873092 | AIDS | A pilot study of microbial signatures of liver disease in those with HIV mono-infection in Rio de Janeiro, Brazil. | 2022 | Details |
| A01089 | 34871813 | Clin Gastroenterol Hepatol | An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. | 2021 | Details |